Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22009966 | 0.85 | HKDC1 (0.52) | TAAR1LMNAHKDC1TRPA1AOC3 | |
| SCHEMBL3126772 | 0.80 | TAAR1 (0.61) | TAAR1LMNAHKDC1AOC3KMT2A | |
| SCHEMBL28411588 | 0.79 | TAAR1 (0.45) | TAAR1LMNAHKDC1TRPA1AOC3 | |
| SCHEMBL13909501 | 0.79 | TRPA1 (0.52) | TAAR1LMNAHKDC1TRPA1AOC3 | |
| SCHEMBL11679334 | 0.79 | TAAR1 (0.67) | TAAR1LMNAHKDC1TRPA1AOC3 | |
| SCHEMBL12803686 | 0.79 | TAAR1 (0.45) | TAAR1LMNAHKDC1TRPA1AOC3 | |
| SCHEMBL3122344 | 0.79 | TAAR1 (0.45) | TAAR1LMNAHKDC1TRPA1AOC3 | |
| SCHEMBL3087075 | 0.78 | TAAR1 (0.44) | TAAR1LMNAHKDC1TRPA1AOC3 | |
| SCHEMBL6526877 | 0.78 | TRPA1 (0.53) | TAAR1TRPA1ADRA1A | |
| SCHEMBL15736894 | 0.76 | TAAR1 (0.42) | TAAR1LMNAHKDC1TRPA1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620425-B1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-12-24 | — | — | EP | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1620425-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092156-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | GLP1R, GCGR, GPR119 | TAAR1 74/4885LMNA 4304/4885HKDC1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.